Pharmacological inhibition of CRM1 mediated by selinexor, the first‐in‐class selective inhibitor of CRM1, mitigates the senescent phenotype of Hutchinson‐Gilford progeria syndrome (HGPS) patients‐derived primary fibroblasts. This evidence concerns the gene XPO1 and Hutchinson-Gilford progeria syndrome.